web-based interactive response (Endpoint Clinical)
90
Structured Review
Endpoint Clinical
web-based interactive response
Web Based Interactive Response, supplied by Endpoint Clinical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/web-based+interactive+response+system/interactive+web+based+response+system/pm39037779-53-5-8
Average 90 stars, based on 1 article reviews
Web Based Interactive Response, supplied by Endpoint Clinical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/web-based+interactive+response+system/interactive+web+based+response+system/pm39037779-53-5-8
Average 90 stars, based on 1 article reviews
web-based interactive response - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Reducing postsurgical exudate in breast cancer patients by using San Huang decoction to ameliorate inflammatory status: a prospective clinical trial Article Snippet: Randomization was accomplished through an Article Title: ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study) Article Snippet: Randomization was accomplished through an Article Title: Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial Article Snippet: Background Diacylglycerol-O-acyltransferase 2 (DGAT2) is one of two enzyme isoforms that catalyse the final step in the synthesis of triglycerides.. IONIS-DGAT2Rx is an antisense oligonucleotide inhibitor of DGAT2 that is under clinical investigation for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).. The aim of this trial was to examine the safety, tolerability, and efficacy of IONIS-DGAT2Rx versus placebo in reducing liver fat in patients with type 2 diabetes and NAFLD. Article Title: Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. Article Snippet: Randomization was accomplished through an Article Title: Monoclonal Antibody Risankizumab for Ulcerative Colitis. Article Snippet: Edouard Louis, MD; Stefan Schreiber, MD; Remo Panaccione, MD; Peter Bossuyt, MD, PhD; Luc Biedermann, MD; Jean-Frederic Colombel, MD; Gareth Parkes, MD, PhD; Laurent Peyrin-Biroulet, MD; Geert D’Haens, MD, PhD; Tadakazu Hisamatsu, MD; Britta Siegmund, MD; Kaichun Wu, MD; Brigid S. Boland, MD; Gil Y. Melmed, MD; Alessandro Armuzzi, MD; Phillip Levine, MDCM; Jasmina Kalabic, MD; Su Chen, PhD; Ling Cheng, PhD; Lei Shu, PhD; W. Rachel Duan, MD, PhD; Valerie Pivorunas, PhD; Yuri Sanchez Gonzalez, PhD; Ronilda D’Cunha, PhD; Ezequiel Neimark, MD; Kori Wallace, MD, PhD; Raja Atreya, MD; Marc Ferrante, MD, PhD; Edward V. Loftus Jr, MD; for the INSPIRE and COMMAND Study Group Article Title: Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3) Article Snippet: Randomization was accomplished through an Article Title: A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries Article Snippet: Randomization was performed using a centralized Article Title: The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial. Article Snippet: If after review of treatment diaries and returned placebo vials adherence was confirmed, participants were randomized, stratified by |